Results 71 to 80 of about 27,037 (216)

Loss of LafB activity reverses daptomycin resistance in E. faecium

mBio
Infections caused by multidrug-resistant enterococci, particularly vancomycin-resistant Enterococcus (VRE), present significant therapeutic challenges. Daptomycin, a last-line treatment for VRE, often loses efficacy due to the emergence of resistance. In
Suelen Scarpa de Mello, Bailey Schultz, Byoungsook Goh, Alexandra Grote, Terrance Shea, Jacob Muscato, Sungwhan F. Oh, Abigail L. Manson, Ashlee M. Earl, Suzanne Walker, Ilana L. B. C. Camargo, Michael S. Gilmore   +11 more
doaj   +1 more source

Influence of the minimum inhibitory concentration of daptomycin on the outcomes of Staphylococcus aureus bacteraemia

Journal of Global Antimicrobial Resistance, 2021
Objectives: Recent studies have shown that methicillin-resistantStaphylococcus aureus (MRSA) bacteraemia with vancomycin minimum inhibitory concentration (MIC) >1 μg/mL is associated with a higher rate of treatment failure and a higher mortality rate ...
Hajar AlQahtani, Saeed Baloch, Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani, Deanne Tabb   +4 more
doaj   +1 more source

Daptomycin-nonsusceptible Staphylococcus aureus: the role of combination therapy with daptomycin and gentamicin [PDF]

, 2015
Reduced susceptibility to daptomycin in Staphylococcus aureus has now been described, leading to clinical failures. Here we determined the impact of daptomycin and gentamicin combination therapy on bactericidal activity and resistance emergence using ...
Peleg, Anton Y, Jhih-Hang Jiang, Jiang, Jhih-Hang, Anton Peleg   +3 more
core   +1 more source

Transcriptional Regulator DasR Represses Daptomycin Production through Both Direct and Cascade Mechanisms in Streptomyces roseosporus

Antibiotics, 2022
Daptomycin, produced by Streptomyces roseosporus, is a clinically important cyclic lipopeptide antibiotic used for the treatment of human infections caused by drug-resistant Gram-positive pathogens.
Qiong Chen, Jianya Zhu, Xingwang Li, Ying Wen   +3 more
doaj   +1 more source

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens

, 2010
Andres Beiras-Fernandez1,*, Ferdinand Vogt1,*, Ralf Sodian1, Florian Weis21Department of Cardiac Surgery, University Hospital Großhadern, Ludwig-Maximilian-University, Munich, Germany; 2Department of Anesthesiology, University Hospital Gro& ...
Ferdin, Florian Weis, Ralf Sodian, Andres Beiras-Fernandez, Vogt, et al.   +5 more
core   +1 more source

The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis

Scientific Reports, 2023
Daptomycin is a cyclic lipodepsipeptide antibiotic reserved for the treatment of serious infections by multidrug-resistant Gram-positive pathogens. Its mode of action is considered to be multifaceted, encompassing the targeting and depolarization of ...
Binayak Rimal, James Chang, Chengyin Liu, Raiyan Rashid, Manmilan Singh, Sung Joon Kim   +5 more
doaj   +1 more source

Varied Contribution of Phospholipid Shedding From Membrane to Daptomycin Tolerance in Staphylococcus aureus

Frontiers in Molecular Biosciences, 2021
It has been suggested that daptomycin can be inactivated by lipids released by Staphylococcus aureus and that this effect is antagonized by phenol soluble modulins (PSMs), which bind to the shed lipids.
Tianwei Shen, Kelly M. Hines, Nathaniel K. Ashford, Brian J. Werth, Libin Xu   +4 more
doaj   +1 more source

Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost

Frontiers in Microbiology, 2017
Daptomycin remains as one of the main treatment options for Methicillin-Resistant Staphylococcus aureus (MRSA). Sporadic resistance cases reported in patients treated with either daptomycin or glycopeptides are a growing concern.
Melanie Roch, Paula Gagetti, Paula Gagetti, James Davis, James Davis, Paola Ceriana, Laura Errecalde, Alejandra Corso, Adriana E. Rosato   +8 more
doaj   +1 more source

Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

PLoS ONE, 2012
BackgroundDaptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the genetic evolution to daptomycin resistance in S.
Anton Y Peleg, Spiros Miyakis, Doyle V Ward, Ashlee M Earl, Aileen Rubio, David R Cameron, Satish Pillai, Robert C Moellering, George M Eliopoulos   +8 more
doaj   +1 more source

Daptomycin: a comparison of two intravenous formulations

Drug Design, Development and Therapy, 2018
Celeste Frankenfeld, Sachin Mittal, Yanira Melendez, Luke Mendez-Vigo, Kenneth C Lamp, Kaitlin N Keller, Shellie R Bertolami Merck & Co., Inc., Kenilworth, NJ, USA Abstract: Daptomycin is a cyclic lipopeptide antibacterial agent with potent ...
Frankenfeld C, Mittal S, Melendez Y, Mendez-Vigo L, Lamp KC, Keller KN, Bertolami SR   +6 more
doaj